tiprankstipranks
Trending News
More News >
Co-Diagnostics Inc (CODX)
NASDAQ:CODX

Co-Diagnostics (CODX) AI Stock Analysis

Compare
1,555 Followers

Top Page

CO

Co-Diagnostics

(NASDAQ:CODX)

Rating:39Underperform
Price Target:
$0.50
▲(72.41%Upside)
The overall score reflects significant financial challenges facing Co-Diagnostics, with declining revenue and profitability. Technical indicators suggest bearish market sentiment, and valuation metrics are poor due to negative earnings. Despite advances in its product pipeline, financial difficulties remain the most significant factor affecting the stock.
Positive Factors
Facilities and Infrastructure
The company has inaugurated a new manufacturing facility in South Salt Lake to manufacture its patented Co-Primers oligonucleotides, the Co-Dx PCR Pro instrument, and test cups for the new Co-Dx PCR platform.
Manufacturing Expansion
Production work flows are streamlined, efficiently staffed and ready for expansion in the company's new manufacturing facility in South Salt Lake.
Product Development
The company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, following the collection of clinical evaluation data to support the new test's performance.
Negative Factors
Capital Requirements
The company may need to raise additional capital within the next period due to cash flows from operating activities being ($8.7M) during 1Q25.
Financial Performance
Revenue for the full year 2024 was $3.9M, representing a 43% year-over-year decline.
Regulatory Hurdles
The company withdrew its 510(k) application for its Co-Dx PCR COVID-19 test due to concerns about shelf-life stability.

Co-Diagnostics (CODX) vs. SPDR S&P 500 ETF (SPY)

Co-Diagnostics Business Overview & Revenue Model

Company DescriptionCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
How the Company Makes MoneyCo-Diagnostics makes money primarily through the sale of its diagnostic tests and reagents. These products are used by laboratories, healthcare facilities, and research institutions to detect and analyze various biological markers for infectious diseases and genetic conditions. The company also generates revenue through licensing its proprietary molecular diagnostic technologies to other firms. Key revenue streams include the direct sales of test kits, licensing agreements, and potential partnerships with healthcare providers or governmental health agencies that require advanced diagnostic capabilities. Additionally, Co-Diagnostics may engage in research collaborations that can provide additional funding and revenue opportunities.

Co-Diagnostics Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: -19.44%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
Co-Diagnostics is making significant strides in developing and preparing its Co-Dx PCR platform and related diagnostic tests for market entry. However, the company faces financial challenges, including a significant decrease in revenue and ongoing net losses. Plans for clinical evaluations and regulatory submissions are underway, supported by strong partnerships and grants, but depend on external factors like disease prevalence.
Q1-2025 Updates
Positive Updates
Advancement of Co-Dx PCR Platform
Significant progress on Co-Dx PCR platform, with clinical evaluations planned for TB, COVID-19, respiratory, and HPV tests. Support from organizations like Bill & Melinda Gates Foundation and NIH's RADx Tech program.
TB Test Development and Market Potential
Successful preliminary studies for TB test and preparations for evaluations in India and South Africa, targeting high-demand markets with existing infrastructure in place.
4-Plex Respiratory Panel and HPV Panel Progress
Development supported by NIH's RADx Tech and Bill & Melinda Gates Foundation grants, targeting critical health needs with planned clinical evaluations in 2025.
Engagement and Awareness Initiatives
Participation in events like International HPV Awareness Day, enhancing visibility and stakeholder engagement for the Co-Dx PCR platform.
Negative Updates
Significant Revenue Decline
First quarter revenue decreased to $0.1 million from $0.5 million in the prior year, indicating financial challenges.
Continued Net Loss
Net loss of $7.5 million in Q1 2025, despite a decreased loss compared to the prior year, reflecting ongoing financial struggles.
Dependence on External Factors for Clinical Trials
Timing for COVID-19 test trials dependent on COVID-19 prevalence, impacting submission timelines.
Company Guidance
During the first quarter of 2025, Co-Diagnostics made significant strides in advancing its Co-Dx PCR platform and associated test pipeline, including preparations for clinical evaluations of tests for tuberculosis (TB), COVID-19, a 4-plex respiratory panel, and an 8-plex HPV panel. The company is gearing up to submit an updated version of its COVID-19 test for FDA 510(k) clearance, following extensive verification testing and design improvements. Co-Diagnostics plans to initiate clinical evaluations for these tests in India and South Africa later in 2025, leveraging its joint venture CoSara Diagnostics for regulatory and commercial infrastructure. Financially, Co-Diagnostics reported a first-quarter revenue decrease to $0.1 million from $0.5 million in the prior year, with total operating expenses reduced to $8.6 million and a net loss of $7.5 million. The company ended the quarter with $21.5 million in cash and equivalents, focusing on maintaining a healthy balance sheet and progressing its development pipeline.

Co-Diagnostics Financial Statement Overview

Summary
Co-Diagnostics is encountering financial difficulties with declining revenues and profitability. The balance sheet shows stability with low leverage, but the negative cash flow and earnings present significant challenges. The company needs to improve operational efficiency and cash management.
Income Statement
35
Negative
Co-Diagnostics has experienced a significant decline in revenue from its peak in 2021. The net income has turned negative, reflecting a challenging profitability landscape. Gross profit margins remain relatively high, but the negative EBIT and EBITDA margins indicate operational inefficiencies. The company needs to address these issues to return to profitability.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with minimal debt, resulting in a low debt-to-equity ratio. However, the declining total assets and stockholders' equity indicate financial deterioration. The equity ratio remains solid, suggesting stability, but the negative return on equity highlights profitability concerns.
Cash Flow
30
Negative
Co-Diagnostics is facing negative free cash flow, primarily due to significant operating cash outflows. Despite positive investing cash flows, the inability to generate positive free cash flow to net income ratios suggests challenges in cash management and sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.00M3.92M6.81M34.22M97.89M74.55M
Gross Profit-122.70K2.92M2.63M28.74M86.31M57.96M
EBITDA-36.02M-38.70M-41.48M-10.31M46.40M41.83M
Net Income-35.86M-37.64M-35.33M-14.24M36.66M42.48M
Balance Sheet
Total Assets55.15M64.00M95.32M123.09M160.03M71.24M
Cash, Cash Equivalents and Short-Term Investments21.48M29.75M58.55M81.26M89.86M47.31M
Total Debt1.93M2.15M2.99M347.92K0.000.00
Total Liabilities1.85M9.69M9.31M8.57M25.56M4.54M
Stockholders Equity47.92M54.31M86.01M114.52M134.48M66.70M
Cash Flow
Free Cash Flow-29.85M-29.90M-23.45M5.14M40.41M27.39M
Operating Cash Flow-29.41M-29.16M-22.08M6.57M41.08M28.17M
Investing Cash Flow7.76M17.07M15.39M-58.17M4.10M-5.82M
Financing Cash Flow458.66K103.91K-1.36M-14.03M450.40K19.74M

Co-Diagnostics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.29
Price Trends
50DMA
0.30
Negative
100DMA
0.39
Negative
200DMA
0.70
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
52.16
Neutral
STOCH
70.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CODX, the sentiment is Neutral. The current price of 0.29 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.30, and below the 200-day MA of 0.70, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 70.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CODX.

Co-Diagnostics Risk Analysis

Co-Diagnostics disclosed 23 risk factors in its most recent earnings report. Co-Diagnostics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Co-Diagnostics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$10.66M0.84-499.57%-33.92%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
49
Neutral
$7.84M-72.70%5.05%26.13%
48
Neutral
$20.77M-329.16%2115.38%-4.40%
39
Underperform
$9.37M-56.80%-91.22%11.84%
37
Underperform
$161.35K
-2.99%59.87%
23
Underperform
$4.73M-439.23%56.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CODX
Co-Diagnostics
0.29
-0.96
-76.80%
AXDXQ
Accelerate Diagnostics
0.01
-1.14
-99.13%
BMRA
Biomerica
3.23
-0.26
-7.45%
PAVM
PAVmed
0.59
-0.12
-16.90%
ADGM
Adagio Medical Holdings
1.53
-9.99
-86.72%
MOVE
Movano
0.69
-4.09
-85.56%

Co-Diagnostics Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
Co-Diagnostics Holds Annual Shareholders Meeting
Neutral
May 29, 2025

On May 28, 2025, Co-Diagnostics, Inc. held its annual shareholders meeting where several key proposals were voted on. Shareholders elected directors for a one-year term, approved the 2025 Equity Incentive Plan, adopted a non-binding resolution on executive compensation, and ratified the appointment of Tanner LLC as the independent registered public accounting firm for 2025. These decisions reflect ongoing corporate governance and strategic planning efforts, potentially impacting the company’s operational focus and stakeholder interests.

The most recent analyst rating on (CODX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 17, 2025